Parexel has announced the appointment of Jim Anthony as Chief Commercial Officer and President of Parexel Biotech, enhancing ...

Biohaven › On a very good Friday for the stock market, Biohaven's (NYSE: BHVN) performance was exceptional. The clinical-stage biotech's share price inflated by over 6% that trading session thanks to ...

CEO Christopher Gibson was one of those sellers, with a Thursday reveal that he had sold 40,390 shares of Recursion's common ...

RALEIGH, N.C. (WTVD) -- With so much uncertainty in the job market, along with concerns about funding for higher education, ...

A Cambridge biomedical research institute that launched last year with a roughly $600 million venture capital investment has ...

TC BioPharm CEO Bryan Kobel's service dog was seen plummeting to the pavement during a violent Uber driver attack in April.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $209.8, a high estimate of $240.00, and a low estimate of $166.00. A negative shift in sentiment ...

I maintain a Strong Buy on Krystal Biotech, as the pause in melanoma trial enrollment is offset by promising progress in ...

No doubt, Nigerian scientists are making global contributions in various fields of science and technology. They have ...

NEW YORK – Krystal Biotech has discontinued a Phase I/II clinical trial evaluating an injected version of its gene therapy KB707 in locally advanced or metastatic solid tumors, including melanoma.

Windtree Therapeutics plunges 77% after Nasdaq delisting notice, raising questions about its BNB treasury strategy and future ...

Good morning. The Supreme Court is allowing the Trump administration to cut $783 million in research grants tied to DEI work.